01—Abstract
Summary
Summary of the 8-K filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.
Amgen reported first quarter 2025 results on May 1, 2025, with total revenues up 9% to $8.1 billiona and product sales up 11% to $7.9 billion, driven by 14% volume growth partially offset by 6% lower net selling price.
U.S. product sales grew 14%. Fourteen products delivered at least double-digit growth, including Repatha, BLINCYTO, TEZSPIRE, EVENITY, TAVNEOS and UPLIZNA, and the new launch IMDELLTRA generated $81 millionb in its first full quarter. Non-GAAP EPS rose 24% to $4.90 from $3.96, and non-GAAP operating margin expanded 2.5 points to 45.7%.
GAAP diluted EPS of $3.20c was inflated by a $1.29 billion net gain on the BeiGene equity stake, which was partly offset by an $800 million non-cash impairment of the Otezla intangible asset. Cash generation and balance sheet items were mixed. Free cash flow was $1.0 billion versus $0.5 billion a year earlier, though the prior-year comparison was depressed by an $800 million tax deposit.
Amgen reduced principal debt by $2.8 billiond, ending the quarter with $57.4 billion in debt and $8.8 billion in cash. No shares were repurchased in the quarter, and the dividend was raised 6%. Management reiterated its 2025 guidance of $34.3 to $35.7 billion in revenue and non-GAAP EPS of $20.00 to $21.20, while noting that the outlook excludes possible future tariffs.
For investors, the key watch items are the sustainability of volume-led growth as net pricing erodes, the competitive pressure from biosimilars on Prolia, XGEVA and Enbrel in the second half of 2025, and the pipeline catalysts expected in H2 2025, including MariTide Phase 2 data, the VESALIUS-CV outcomes readout and rocatinlimab maintenance and adolescent data. Because GAAP earnings are heavily affected by mark-to-market equity gains and acquisition amortization, the non-GAAP figures are a better gauge of underlying operating performance, though GAAP earnings guidance also carries a wide range.
02—Key points
Key Highlights
- Total revenues rose 9% to $8.1 billion; product sales grew 11% to $7.9 billion, driven by 14% volume growth partially offset by 6% lower net selling price.
- Non-GAAP EPS increased 24% to $4.90 from $3.96; non-GAAP operating margin expanded 2.5 points to 45.7%.
- GAAP diluted EPS of $3.20 included a $1.29 billion net gain on the BeiGene equity investment and an $800 million non-cash Otezla intangible asset impairment.
- Free cash flow of $1.0 billion versus $0.5 billion a year earlier; the comparison was affected by an $800 million tax deposit in Q1 2024.
- Repatha (+27%), BLINCYTO (+52%), TEZSPIRE (+65%) and TAVNEOS (+76%) led growth, with fourteen products posting at least double-digit sales increases.
- Reduced principal debt by $2.8 billion to $57.4 billion; no share repurchases in the quarter; quarterly dividend raised 6%.
- 2025 guidance reaffirmed: revenue of $34.3–$35.7 billion, non-GAAP EPS of $20.00–$21.20, and capex of about $2.3 billion, excluding potential future tariffs.
03—Questions
Frequently Asked Questions
Why did GAAP EPS ($3.20) differ so much from non-GAAP EPS ($4.90)?
The gap mainly reflects non-cash items. Amgen recorded a $1.29 billion net gain from its BeiGene equity stake, which boosted GAAP results, and an $800 million impairment of the Otezla intangible asset, which reduced them. Acquisition-related amortization from the Horizon deal, about $1.5 billion in cost of sales, is also excluded from non-GAAP results. Management views non-GAAP as the better measure of ongoing operations.
Is Amgen's growth driven by volume or pricing?
Volume. Product sales grew 11% overall, with 14% volume growth offset by 6% lower net selling price. Net pricing pressure came from items such as 340B mix and commercial discounts on Enbrel, which saw a 47% drop in net selling price, although management expects that year-over-year effect to ease in future quarters.
What are the main risks to revenue in the coming quarters?
Biosimilar competition is the central risk. Management expects sales erosion for Prolia and XGEVA, particularly in the second half of 2025, and continued erosion for MVASI. Enbrel and AMJEVITA face pricing pressure, and KYPROLIS is losing volume to competitors. Guidance also excludes possible future tariffs, including sector-specific ones.
What pipeline catalysts should investors watch in 2025?
Several readouts are expected in H2 2025, including MariTide Phase 2 chronic weight management Part 2 and T2D data, the VESALIUS-CV Repatha outcomes study, and rocatinlimab ROCKET ASCEND and ASTRO data. Near term, the FORTITUDE-101 bemarituzumab Phase 3 readout is due in Q2 2025, and IMDELLTRA's DeLLphi-304 detailed data will be presented at ASCO in June. PDUFA dates include TEZSPIRE's WAYPOINT indication on October 19, 2025, and UPLIZNA's gMG indication on December 14, 2025.
How strong is Amgen's balance sheet and cash position?
Cash and equivalents were $8.8 billion and total debt was $57.4 billion at March 31, 2025, down from $60.1 billion at year-end 2024. Quarterly free cash flow of $1.0 billion covered the $1.3 billion in dividends only partly, with the rest funded from cash on hand and debt reduction. Management did not buy back shares in Q1, and 2025 buybacks are capped at $500 million.
04—Continue